BIIB
$320.48
Biogen
$1.40
.44%
BIIB
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  $6.72
Revenue:  $3.38 Bil
Tuesday
Jan 22
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when BIIB reports earnings?
Beat
Meet
Miss

Where is BIIB's stock price going from here?
Up
Flat
Down
Stock chart of BIIB
Analysts
Summary of analysts' recommendations for BIIB
Score
Grade
Pivots
Resistance
$330.91
$328.09
$323.58

$320.76

Support
$316.25
$313.43
$308.92
Tweet
Growth
Description
IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Their first commercial product, Rituxan, and our most advanced product candidate, ZEVALIN, are for use in the treatment of certain B-cell non-Hodgkin's lymphomas. They are also developing products for the treatment of various autoimmune diseases (such as psoriasis, rheumatoid arthritis and lupus).
Peers
Gilead SciencesAmgenBluebird BioNeurocrine BiosciencesSeattle GeneticsQiagen N.V.BioCryst PharmaceuticalsRepligenSangamo TherapeuticsBio-Techne